Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial

Eli Lilly and Co. (NYSE:LLY) on Wednesday presented new clinical data showing the lasting benefits of a dual-drug approach for active psoriatic arthritis.

Detailed 52-week results indicate sustained and enhanced efficacy when combining two specific therapies, offering a positive outlook for patients managing multiple health conditions.

TOGETHER-PsA Clinical Trial

The recent data originates from the TOGETHER-PsA Phase 3b open-label clinical trial.

During this study, researchers assessed the concomitant administration of Taltz (ixekizumab) and Zepbound, or tirzepatide. The trial directly compared this combined regimen against the administration of Taltz on its own.

Sustained Long-Term Improvements

The composite outcome of psoriatic arthritis disease activity (ACR50) plus at least 10% weight reduction was achieved at Week 52 by 39.2% of the combination arm and 1.7% of the Taltz-alone arm, compared with 31.7% and 0.8%, respectively, at Week 36.

85.7% of combination patients and 6.7% of monotherapy patients achieved at least 10% weight reduction at one year.

Lilly reported that ACR50 responses began separating between the arms as early as Week 4, before clinically meaningful weight loss was observed.

Participants taking Taltz and Zepbound together maintained their initial health gains. In many cases, the patients showed further improved outcomes as they progressed through Week 52 of the trial.

The combination therapy delivered these sustained improvements across several critical health metrics.

The clinical team observed continued progress in overall disease activity and crucial metabolic measures. Additionally, the trial recorded ongoing advancements in various patient-reported outcomes over the course of the year.

Surpassing Earlier Milestones

These comprehensive 52-week findings build heavily upon the trial’s earlier achievements. As previously reported by the company, the Taltz and Zepbound combination already met the primary endpoint of the study at 36 weeks.

Minimal disease activity was achieved at Week 52 by 28.2% of the combination arm and 13.6% of the monotherapy arm.

The dual therapy also achieved all key secondary endpoints at that 36-week threshold.

During this earlier phase, the combination treatment demonstrated statistically significant superiority when compared directly to the Taltz-only regimen.

LLY Price Action: Eli Lilly shares were down 0.45% at $1425.79 at the time of publication on Wednesday. The stock is trading near its 52-week high of $1453.00, according to Benzinga Pro data.

Photo by Doucefleur via Shutterstock